Global WholeHealth Partners Corp (OTC: GWHP) Has Paid Off Another of Its Outstanding Convertible Notes as Stated in the 8K Filed on 02/17/21
Global WholeHealth Partners Corp (OTC: GWHP) has successfully eliminated a second convertible note, marking a significant financial milestone. This payment was made possible through a direct equity investment from a healthcare investor, thereby avoiding potential dilution for existing shareholders. The company is now focusing on securing long-term capital investments to strengthen its financial foundation. With FDA EUA authorized COVID-19 testing products and an anticipated introduction of a rapid Antigen test, Global is poised for growth in a rapidly evolving market.
- Elimination of a convertible note reduces debt and avoids shareholder dilution.
- Focus on long-term capital investments strengthens financial foundation.
- FDA EUA authorized COVID-19 testing products position the company favorably in the market.
- None.
Eliminating the second convertible note represents a significant milestone for Global WholeHealth Partners Corp.
San Clemente, CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp (OTC: GWHP), has paid off another of its outstanding convertible notes as stated in the 8K filed on 02/17/21. The note was paid from a direct equity investment by a healthcare investor.
Eliminating the second convertible note represents a significant milestone for Global WholeHealth Partners Corp (OTC:GWHP); Global will seek capital from longer term investments. Global is building a stronger financial base, by eliminating debt. Since the note was not converted into shares under the original terms, we were also able to avoid substantial dilution to our shareholders.
Given our outlook for strong growth this year and the rapidly improving fundamentals of the business, Global is getting into a position where we hopefully can fund our growth from cash flow from operations or from capital equity sources.
The strong growth outlook comes from Global leading the way in the fight against CoViD19, by offering 15 Minute Rapid IgG/IgM Tests for Venous Blood, & Fingertip Blood (POC), and 90 Minute rt-PCR Tests for CoViD19 with All the Tests Being FDA EUA Authorized, one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2.
About Global WholeHealth Partners Corp.:
Global WholeHealth Partners Corp, knowing that the next step in the fight against CoViD19 SARS2 is the Antigen test, has already filed with the FDA the PEUA Application # PEUA201789 for the Rapid 10 minute Nasal Antigen Test. Global's version of the Antigen test does not need a machine to read the results.
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingertip test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like Rapid Ebola, ZIKA, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests. Global is planning to be able to offer an Antigen Rapid Test soon.”
Global WholeHealth Partners Corp (GWHP: OTC) offers all the formats for testing CoViD 19 SARS 2. Global has the Antibody IgG/IgM Rapid antibody, including the POC (Point of Care), the rtPCR CoViD 19 SARS test, which works on any machine; these entire tests are FDA EUA AUTHORIZED.
Global also offers for international sales the Antigen Rapid IgA test, which is not FDA EUA Authorized.
Call 1-877-568-GWHP (4947) to become a distributor or buy FDA EUA Authorized SARS-COV-2 IgG/IgM Antibody Whole Blood, Serum and Plasma Rapid Test kits, or the Point of Care IgG/IgM fingertip blood format or the rtPCR test.
For more details: https://gwhpcorp.com
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: Sales@gwhpcorp.com
Symbol: GHWP
Forward-Looking Statements
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is the significance of Global WholeHealth Partners eliminating the convertible note on February 24, 2021?
What impact does Global WholeHealth Partners' FDA EUA authorized testing products have on GWHP stock?
What are the future plans for Global WholeHealth Partners regarding COVID-19 testing?
How is Global WholeHealth Partners addressing the COVID-19 pandemic?
